Duke-NUS Partners Singapore Start-Up CoVBio to Develop Broad-Spectrum COVID-19 Vaccines, Therapeutics
September 17, 2022
September 17, 2022
SINGAPORE, Sept. 17 (TNSpar)(TNSjou) -- Duke-NUS Graduate Medical School issued the following news release:
Duke-NUS Medical School has signed an exclusive worldwide licensing agreement with Singapore start-up CoV Biotechnology (CoVBio) to develop broad-spectrum vaccines and therapeutic antibodies that could potentially protect the world's population from future coronavirus pandemics. Taking this game-changing medical technology a step closer to reality, a novel consensus seque . . .
Duke-NUS Medical School has signed an exclusive worldwide licensing agreement with Singapore start-up CoV Biotechnology (CoVBio) to develop broad-spectrum vaccines and therapeutic antibodies that could potentially protect the world's population from future coronavirus pandemics. Taking this game-changing medical technology a step closer to reality, a novel consensus seque . . .